| 4.89 Data as of 11:11am ET |  +0.14 / +2.95%Today’s Change | 4.03 Today|||52-Week Range 6.85 | +16.43% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $87.6M |
Company Description
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the acquisition, development and commercialization of branded prescription products. Its target markets are hospital acute care and gastroenterology. The company's product portfolio includes Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) injection, a treatment for pain and fever, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome. Cumberland Pharmaceuticals was founded by A. J. Kazimi in 1999 and is headquartered in Nashville, TN.
Employees
Shareholders
| Individual stakeholders | 39.65% |
| Other institutional | 23.34% |
| Mutual fund holders | 10.48% |
Top Executives
| A. J. Kazimi, MBA | Chairman & Chief Executive Officer |
| Leo Pavliv, MBA | Chief Development Officer & Senior VP-Operations |
| Rick Scott Greene | Chief Financial Officer & VP-Accounting |
| Gordon R. Bernard, MD | Director |
| Amy Dix Rock, PhD, MBA | Senior Director-Regulatory & Scientific Affairs |
.
